Get the Stockscreener App
14.34
0.14%
-0.02
Pre-market:
14.26
-0.08
-0.56%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $14.34, with a volume of 7.62M.
It is down -0.14% in the last 24 hours and up +15.93% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$14.36
Open:
$14.27
24h Volume:
7.62M
Relative Volume:
0.86
Market Cap:
$16.52B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-4.5237
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+9.72%
1M Performance:
+15.93%
6M Performance:
+59.69%
1Y Performance:
+30.96%
1-Day Range:
$14.22
$14.44
1-Week Range:
$12.93
$14.49
52-Week Range:
$6.85
$14.49
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.34 | 16.54B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.80 | 56.04B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.73 | 55.84B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.86 | 48.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.80 | 40.20B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
478.93 | 20.78B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Announces Chief Legal Officer Transition and Successor - TipRanks
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - The AI Journal
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - Viatris
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $13.49 - Investing.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What Are Wall Street Analysts' Target Price for Viatris Stock? - Yahoo Finance
What Does the Market Think About Viatris Inc? - Benzinga
Piper Sandler raises Viatris stock price target to $12 on brand strength - Investing.com UK
Piper Sandler raises Viatris stock price target to $12 on brand strength By Investing.com - Investing.com Nigeria
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Viatris launches ‘EmpowerED for Life’ for men’s health in Africa - MSN
Should Viatris’ (VTRS) First Inpefa UAE Launch Shape Investor Views on Its Innovation Strategy? - simplywall.st
Understanding the Setup: (VTRS) and Scalable Risk - Stock Traders Daily
Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch - Yahoo Finance
Viatris Earnings Preview: What to Expect - Barchart.com
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria
Viatris launches heart failure drug Inpefa in UAE, first outside US By Investing.com - Investing.com South Africa
3 Reasons to Sell VTRS and 1 Stock to Buy Instead - Finviz
Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途牛牛
Viatris Launches Inpefa in United Arab Emirates - marketscreener.com
Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq
Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - Sahm
Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India
Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Argus Research Upgrades Viatris (VTRS) - Nasdaq
Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues
Viatris stock tests multi-year ceiling after impressive rally - FXStreet
United States Treatment-Resistant Depression Market to grow - openPR.com
Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz
RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn
Contact UsCeres CourierViatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²
Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Viatris Stock: Is Wall Street Bullish or Bearish? - MSN
Viatris hits main goals in Phase 3 trial for birth control patch - MSN
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):